FDA approval of Filkri expands Accord’s G-CSF biosimilar portfolio, offering a short-acting option for neutropenia in cancer care.
The Food and Drug Administration (FDA) has approved Filkri ® (filgrastim-laha), a biosimilar to Neupogen ® (filgrastim). Filkri, a leukocyte growth factor, is approved to: ...
The U.S. Food and Drug Administration (FDA) has approved Filkri (filgrastim-laha), a biosimilar to Neupogen (filgrastim), to ...
- APHEXDA is the first innovation in stem cell mobilization for multiple myeloma to be approved in the U.S. in a decade - - One dosage of APHEXDA plus filgrastim enabled a majority of patients to ...
Successful re-initiation of calcineurin inhibitors in patients with posterior reversible encephalopathy syndrome (PRES) No significant financial relationships to disclose. This is an ASCO Meeting ...
Neulasta (pegfilgrastim) is a brand-name drug that’s prescribed to treat radiation sickness and prevent certain complications of chemotherapy. Neulasta comes as an injectable solution. The dosage can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results